 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- | ABBV-011 / AbbVie
Journal: Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma. (Pubmed Central) - Sep 26, 2024
SEZ6 may serve as a novel biomarker for MTCs. Although SEZ6 lacks any prognostic values in MTC, its positivity in 91% to 93% of MTCs, including MTCs without RET and RAS mutations, renders SEZ6-targetted antibody-drug conjugate therapy a promising targeted therapy for MTCs.
- SEZ6 Expression in Neuroendocrine Tumors (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1198;
Among extrapulmonary NE tumors, SEZ6 expression varies by site of origin and is highest in prostate neuroendocrine tumors. These data support further exploration of SEZ6- directed therapy in other neuroendocrine tumors.
- ABBV-706 / AbbVie
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6) (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2164;
P1
ABBV-706 demonstrated a manageable safety profile with promising efficacy in SCLC and NENs. Further evaluation of ABBV-706 is ongoing.
- | ABBV-011 / AbbVie
Preclinical, Journal: Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6 Targeting Antibody Drug Conjugate. (Pubmed Central) - Jan 11, 2024
Significance Statement Several in vitro and in vivo stability studies of ABBV-011, a calicheamicin-based ADC, identified circulating metabolites and catabolites and suggested that disulfide cleavage may be a key liability for the conjugated linker-payload. These observations may be relevant to other disulfide-linked ADCs, such as Mylotarg and Besponsa, both of which have reported similar half-lives that possibly indicate instability.